Matches in Nanopublications for { ?s ?p "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- _4 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.
- _5 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.
- _5 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.
- _6 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.
- _5 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.
- _5 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.
- _4 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.
- _5 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.
- _6 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.
- _5 value "(Jubilant) Pretreatment with C3 transferase exoenzyme, an inhibitor of Rho small GTP binding proteins (Rho A, B and C) inhibited the bradykinin induced NFkB activity. Treatment with calpain I or PDTC completely inhibited the DNA binding activity of NFkB. Transfection of cell with dominant negative RhoA-T19N inhibited the bradykinin induced NFkB activity. A dominant-negative form of RhoA (T19N) inhibited BK-stimulated reporter gene expression in a dose-dependent and kappaB-dependent manner." provenance.